Abstract
Monoamine oxidase-A and B have been studied over a long period as one of the promising drug targets for the treatment of depression and neurodegenerative disorders. Commonly, MAO-A is associated with depression because of its relation with the control of serotonin levels. On the other hand, MAO-B has been associated with Alzheimer’s and Parkinson’s diseases because this enzyme modulates dopamine levels in the CNS. The major objective of the research in this field is devoted to identify and isolate selective ligands of MAO-A/MAO-B so that the undesirable side effects due to non-selective inhibition of monoamine catabolism by the isoforms can be avoided. This review will give an overview of the inhibition mechanism of MOA and its biochemistry, along with the history and development of MAO inhibitors including the significance of molecular modeling studies for the identification of novel class of MAO inhibitors.
Keywords: MAO-A, MAO-B, depression, Parkinson’s disease, cheese effect, docking.
Current Enzyme Inhibition
Title:Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders
Volume: 12 Issue: 2
Author(s): Bijo Mathew, Githa E. Mathew, Jerad Suresh, Gülberk Ucar, Rani Sasidharan, Sockalingam Anbazhagan, Jobin K. Vilapurathu and Venkatesan Jayaprakash
Affiliation:
Keywords: MAO-A, MAO-B, depression, Parkinson’s disease, cheese effect, docking.
Abstract: Monoamine oxidase-A and B have been studied over a long period as one of the promising drug targets for the treatment of depression and neurodegenerative disorders. Commonly, MAO-A is associated with depression because of its relation with the control of serotonin levels. On the other hand, MAO-B has been associated with Alzheimer’s and Parkinson’s diseases because this enzyme modulates dopamine levels in the CNS. The major objective of the research in this field is devoted to identify and isolate selective ligands of MAO-A/MAO-B so that the undesirable side effects due to non-selective inhibition of monoamine catabolism by the isoforms can be avoided. This review will give an overview of the inhibition mechanism of MOA and its biochemistry, along with the history and development of MAO inhibitors including the significance of molecular modeling studies for the identification of novel class of MAO inhibitors.
Export Options
About this article
Cite this article as:
Mathew Bijo, Mathew E. Githa, Suresh Jerad, Ucar Gülberk, Sasidharan Rani, Anbazhagan Sockalingam, Vilapurathu K. Jobin and Jayaprakash Venkatesan, Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders, Current Enzyme Inhibition 2016; 12 (2) . https://dx.doi.org/10.2174/1573408012666160402001715
DOI https://dx.doi.org/10.2174/1573408012666160402001715 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Cognitive Improvement by Photic Stimulation in a Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Spatial Correlations between the Vacuolation, Prion Protein (PrPsc) Deposits and the Cerebral Blood Vessels in Sporadic Creutzfeldt-Jakob Disease
Current Neurovascular Research Effect of Polyherbal Drug Majun Falasfa on the Transgenic Drosophila Model of Parkinson’s Disease
Current Traditional Medicine Editorial
Current Molecular Medicine Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
Current Topics in Medicinal Chemistry Physically Cross-linked Hydrogels of β -cyclodextrin Polymer and Poly(ethylene glycol)-cholesterol as Delivery Systems for Macromolecules and Small Drug Molecules
Current Drug Delivery Exploring Potential of Alkaloidal Phytochemicals Targeting Neuroinflammatory Signaling of Alzheimer's Disease
Current Pharmaceutical Design The Possible Involvement of Glycogen Synthase Kinase-3 (GSK-3) in Diabetes, Cancer and Central Nervous System Diseases
Current Pharmaceutical Design Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry The Neuronal Cytoskeleton as a Potential Therapeutical Target in Neurodegenerative Diseases and Schizophrenia
Current Drug Targets - CNS & Neurological Disorders Editorial: Circadian Rhythms are Everywhere: Except in Neurodegenerative Disorders
Current Alzheimer Research Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Detrimental Effects of Apolipoprotein E4: Potential Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Processing of Amyloid Precursor Protein and Amyloid Peptide Neurotoxicity
Current Alzheimer Research Human PON Promoters: From Similarity to Prediction of Polymorphic Positions within Transcription Factor Elements
Mini-Reviews in Medicinal Chemistry Systematic Evaluation of Drug-Loaded Hydrogels for Application in Osteosarcoma Treatment
Current Pharmaceutical Biotechnology Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets